This is due to the presence of oncogenic driver mutations for NSCLC occurring on ALK, EGFR, ROS1, V-raf murine sarcoma viral oncogene homolog B (BRAF), (MET, NTRK, RET, KRAS, Human epidermal growth factor 2 (HER2) and NRG1 (Chevallier et al., 2021). This evidence concerns the gene ALK and non-small cell lung carcinoma.